Related Experiment Video
Updated: Jun 28, 2026
08:32
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review
Meredith A Morgan1, Leslie A Parsels, Jonathan Maybaum
1Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109-5637, USA. mmccrack@med.umich.edu
Summary
Gemcitabine is a key chemotherapy drug and radiation sensitizer. Combining it with targeted therapies like epidermal growth factor receptor inhibitors may improve efficacy while reducing toxicity in cancer treatment.
Area of Science:
- Oncology
- Cancer Therapeutics
- Molecular Targeted Therapy
Background:
- Gemcitabine has evolved into a standard chemotherapeutic agent and radiation sensitizer over the past 30 years.
- Combinations of gemcitabine with other chemotherapies have shown limited success due to significant toxicity.
- Improving gemcitabine efficacy while managing toxicity is crucial for effective cancer treatment.
Purpose of the Study:
- To review promising molecularly targeted agents for combination with gemcitabine-based chemoradiation.
- To identify strategies for enhancing gemcitabine efficacy with reduced toxicity.
Main Methods:
- Literature review of gemcitabine in cancer therapy.
- Analysis of molecular targets for combination therapies.
- Evaluation of epidermal growth factor receptor and checkpoint kinase 1 as potential targets.
Main Results:
- Gemcitabine is an established chemotherapeutic and radiosensitizer.
- Standard chemotherapy combinations with gemcitabine are limited by toxicity.
- Molecularly targeted agents offer a promising strategy to overcome gemcitabine-related toxicities.
Conclusions:
- Combining gemcitabine with molecularly targeted agents represents a promising strategy to improve chemoradiation efficacy.
- Epidermal growth factor receptor and checkpoint kinase 1 are key targets for enhancing gemcitabine-based therapies.
- Targeted therapies may offer a more tolerable approach to improving outcomes in gemcitabine-treated patients.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...